Bio-IT World News
YouTube Facebook LinkedIn TwitterInstagram rss
a-divisiion-of-chi
  • Subscribe
  • News
    • Latest News
    • View Press Releases
    • Post a Press Release
    • Reprint Articles
  • Podcast
  • Advertise
    • Media Kit
    • Digital Advertising
    • Lead Generation
    • Editorial Calendar
    • Webinars
    • Whitepapers
    • Podcasts
    • View Press Releases
    • Post a Press Release
  • Free Downloads
    • Whitepapers
    • Podcasts
    • Webinars
    • Inside eBooks
  • Events
    • Webinars
    • Industry Events
    • IT Conferences
    • Bio-IT World Expo
    • Bio-IT World Expo Europe
  • About Us
    • Editorial Profile
    • Editorial Calender
    • Contact Us
    • Submit a story
    • Innovative Practices Awards
    • Linking Policy
  • Bio-IT World Expo
    • Bio-IT World Boston
    • Bio-IT World Europe
 
 
 
 
  • From Ordinary to Extraordinary: CD Formulation's Remarkable Food Ingredient Launch

    Feb 7, 2024, 08:09 AM by
    Full story
  • Alfa Chemistry Catalysts: Porphyrin Ligands, Phthalocyanine Ligands Are Newly Released for the Science Community

    Feb 7, 2024, 08:09 AM by
    Full story
  • CD Formulation Shows the Ability of Coated Microneedle Preparation Technology for Novel Drug Delivery

    Feb 7, 2024, 08:09 AM by
    Full story
  • Game-Changing ‘Audit Trail Review’ Application Secures ACDM 2024 Awards Nomination for CluePoints

    Feb 7, 2024, 08:09 AM by
    Game-Changing ‘Audit Trail Review’ Application Secures ACDM 2024 Awards Nomination for CluePoints RBQM Leader Shortlisted for Accolade for Innovation in the Management of Clinical Data
    Full story
  • New Patient Scoring Method To Enable Precision Medicine For Chronic Diseases

    Feb 7, 2024, 01:00 AM by User Not Found
    Bio-IT World | Investigators with The University of New Mexico (UNM) and the National Institutes of Health (NIH) have succeeded in developing a cholesterol-lowering vaccine that works independently of statins. It could become the next vaccine-based approach targeting PCSK9 (proprotein convertase subtilisin/kexin type 9 serine protease) to enter clinical trials.
    Full story
  • Verisense Health Adopts Datavant’s Data Connectivity Platform to Expand its Digital Health Panel’s RWD Sources

    Feb 6, 2024, 09:01 AM by
    Datavant’s privacy-preserving record linkage technology will allow Verisense Health’s digital health data to generate richer patient insights.
    Full story
  • Azenta Launches the BioArc Ultra, a Breakthrough, Automated Solution for Efficient, Eco-Friendly Ultracold Sample Management

    Feb 6, 2024, 09:01 AM by
    Azenta, Inc has announced the launch of the BioArc™ Ultra, a breakthrough, automated solution for high-density, eco-friendly ultracold sample management, designed to provide a new level of performance.
    Full story
  • Showcase on lab automation instruments and consumables on display at SLAS2024 International Conference and Exhibition

    Feb 6, 2024, 09:01 AM by
    Azenta Life Sciences has announced that it will display a range of productivity-enhancing consumables, instruments, and automated sample storage products at SLAS 2024 in Boston, USA from February 5 - 7.
    Full story
  • Integrated DNA Technologies and Element Biosciences Accelerate Next Generation Sequencing Workflows for Element’s AVITI™ System

    Feb 6, 2024, 09:01 AM by
    Integrated DNA Technologies and Element Biosciences are bolstering its partnership to equip AVITI users with differentiated NGS tools.
    Full story
  • Pharmaceutical Targets Identified For Osteoarthritis

    Feb 6, 2024, 01:00 AM by User Not Found
    Bio-IT World | Investigators with The University of New Mexico (UNM) and the National Institutes of Health (NIH) have succeeded in developing a cholesterol-lowering vaccine that works independently of statins. It could become the next vaccine-based approach targeting PCSK9 (proprotein convertase subtilisin/kexin type 9 serine protease) to enter clinical trials.
    Full story
  • SPT Labtech Appoints New Chief Commercial Officer

    Feb 5, 2024, 09:03 AM by
    Full story
  • First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial

    Feb 2, 2024, 09:19 AM by
    Lixe Biotechnology announced the dosing of the first patient in its Phase 1b/2 clinical trial to assess the efficacy of its LB-100 lead molecule with GSK's PD-1-blocking monoclonal antibody, dostarlimab-gxly, in the treatment of ovarian clear cell carcinoma.
    Full story
  • Lindus Health Introduces Bespoke “All-In-One CRO for Digital Therapeutics” Solution to Companies in the Space Streamline Clinical Trials

    Feb 2, 2024, 09:19 AM by
    Lindus Health Introduces Bespoke “All-In-One CRO for Digital Therapeutics” Solution to Companies in the Space Streamline Clinical Trials
    Full story
  • Effortless Measurement of All Four NADs and Glutathione for Laboratories

    Feb 2, 2024, 09:19 AM by
    NADMED has announced an innovative technology designed for effortless extracting and measuring all four NADs and two glutathiones.
    Full story
  • AppOmni Harnesses Google Data Center in Australia to Address Regional Demand for Specialised SaaS Security Solutions

    Feb 1, 2024, 08:53 AM by
    AppOmni, the pioneer of SaaS security posture management (SSPM), proudly announces the establishment of a new data centre in Sydney, Australia, hosted by Google Cloud Platform (GCP). This new initiative brings AppOmni’s comprehensive SaaS security solutions to any organisation—private or public—required to comply with Australia’s data sovereignty regulations, including the Privacy Act and the Australian Privacy Principles. As AppOmni continues its global expansion efforts, Australia remains a strategic location for the company. The new data centre helps address a growing need in the APAC region to counter sophisticated threats targeting SaaS applications. These concerns are echoed by the 25% of Fortune 100 companies that already trust AppOmni to secure their SaaS ecosystems.
    Full story
  • Becky Upton on Effective Data Management, Setting Standards, and Teamwork

    Feb 1, 2024, 01:00 AM by User Not Found
    Bio-IT World | Scientists at the Center for Infection and Immunity (CII) at Columbia University Mailman School of Public Health have created a next-generation sequencing (NGS) technology that employs oligonucleotides (oligos)—short single strands of synthetic DNA—as bait for relevant targets of detection.
    Full story
  • Watson-Marlow to demonstrate latest fluid path technologies at MD&M West

    Jan 31, 2024, 08:28 AM by
    Devens, MA, US / 30th January 2023 / Sciad Newswire / Watson-Marlow Fluid Technology Solutions (WMFTS), a leader in peristaltic pumps and associated fluid path technologies, will showcase its diverse product range specially designed for medical devices and diagnostic instruments at MD&M West in Anaheim, CA, from February 6-8.
    Full story
  • ZeOmega Partners With Datycs to Digitize Faxed Documents and Automate Healthcare Data Workflows

    Jan 31, 2024, 08:28 AM by
    This collaboration allows payers to make processes such as prior authorization more efficient; especially critical given the new requirements for faster turnaround times. Digitizing faxed documents and applying technologies such as AI and NLP to mine data cuts back on manual steps, reducing administrative burden and costs.
    Full story
  • Currax Pharmaceuticals Announces First Patient Screened into the INFORMUS Cardiovascular Outcomes Trial

    Jan 31, 2024, 08:28 AM by
    Currax Pharmaceuticals announces the first patient screened and accepted into the CONTRAVE® INFORMUS Cardiovascular Outcomes Trial (NB-CVOT3).
    Full story
  • Qlucore Diagnostics for Pediatric leukemia takes a Significant step closer to CE marking

    Jan 31, 2024, 08:28 AM by
    Qlucore, a leader in software development for precision cancer diagnostics, has taken the final major step in the process towards a CE-marked medical device for in-vitro diagnostics by submitting the technical documentation to a Notified Body. The CE marked product, Qlucore Diagnostics, is due to be launched in February 2025.
    Full story
  • «
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47 (current)
  • 48
  • 49
  • 50
  • »
 
CHI | Cambridge HealthTech Institute

250 First Avenue, Suite 300
Needham, MA 02494

P: 781.972.5400
F: 781.972.5425
E: chi@healthtech.com

Life Science Portals

Biological Therapeutic Products

Biomarkers & Diagnostics

Biopharma Strategy

Bioprocess & Manufacturing

Chemistry

Clinical Trials &
Translational Medicine

Drug & Device Safety

Drug Discovery & Development

Drug Targets

Healthcare

IT, AI, ML & Informatics

Technology & Tools For
Life Science

Therapeutic Indications

Venture, Innovation & Partnering

CHI Divisions

Conferences

Reports & Market Research

Barnett Educational Services

News & Advertising

Professional Services

Corporate Information

Cambridge Innovation
Institute

Executive Team

Testimonials

Mailing List

Careers


Request Information

Privacy Policy